| Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study GL Willis, EJD Turner Chronobiology international 24 (3), 521-537, 2007 | 162 | 2007 |
| Hypothalamic norepinephrine in the rat during feeding and push-pull perfusion with glucose, 2-DG, or insulin ML McCaleb, RD Myers, G Singer, G Willis American Journal of Physiology-Regulatory, Integrative and Comparative …, 1979 | 130 | 1979 |
| Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative … GL Willis Reviews in the Neurosciences 19 (4-5), 245-316, 2008 | 117 | 2008 |
| Circadian system—a novel diagnostic and therapeutic target in Parkinson's disease? A Videnovic, GL Willis Movement Disorders 31 (3), 260-269, 2016 | 113 | 2016 |
| A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease GL Willis, SM Armstrong Physiology & behavior 66 (5), 785-795, 1999 | 109 | 1999 |
| A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease GL Willis, C Moore, SM Armstrong Reviews in the Neurosciences 23 (2), 199-226, 2012 | 102 | 2012 |
| Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice GL Willis, GA Donnan Brain research 402 (2), 269-274, 1987 | 93 | 1987 |
| Motor function in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mouse GA Donnan, GL Willis, SJ Kaczmarczyk, P Rowe Journal of the neurological sciences 77 (2-3), 185-191, 1987 | 91 | 1987 |
| Ventricular, paraventricular and circumventricular structures involved in peptide-induced satiety GL Willis, J Hansky, GC Smith Regulatory peptides 9 (1-2), 87-99, 1984 | 66 | 1984 |
| Intracranial injections of 6-OHDA. Comparison of catecholamine-depleting effects of different volumes and concentrations GL Willis, G Singer, BK Evans Pharmacology Biochemistry and Behavior 5 (2), 207-213, 1976 | 59 | 1976 |
| The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study JK Martino, CB Freelance, GL Willis Sleep medicine 44, 24-31, 2018 | 47 | 2018 |
| Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the … GL Willis, AD Robertson Pharmacology Biochemistry and Behavior 79 (3), 413-429, 2004 | 47 | 2004 |
| The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease GL Willis, GA Kennedy Reviews in the Neurosciences 15 (1), 75-87, 2004 | 43 | 2004 |
| The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. GL Willis Drug news & perspectives 18 (7), 437-444, 2005 | 38 | 2005 |
| Polychromatic light exposure as a therapeutic in the treatment and management of Parkinson's disease: a controlled exploratory trial GL Willis, J Boda, CB Freelance Frontiers in Neurology 9, 741, 2018 | 35 | 2018 |
| Intraocular microinjections repair experimental Parkinson's disease GL Willis Brain research 1217, 119-131, 2008 | 35 | 2008 |
| Deficits in locomotor behaviour and motor performance after central 6-hydroxydopamine or peripheralL-DOPA GL Willis, GC Smith, BP McGRATH Brain Research 266 (2), 279-286, 1983 | 31 | 1983 |
| The role of some central catecholamine systems in cholecystokinin-induced satiety GL Willis, J Hansky, GC Smith Peptides 5 (1), 41-46, 1984 | 29 | 1984 |
| The behavioural effects of intrahypothalamic multistage versus single injections of 6-hydroxydopamine GL Willis, GC Smith Brain Research 245 (2), 345-352, 1982 | 28 | 1982 |
| Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model GL Willis, AMA Kelly, GA Kennedy Behavioural brain research 193 (1), 37-47, 2008 | 27 | 2008 |
